EDITAS MEDICINE, INC. Research and Development in Process
EDITAS MEDICINE, INC. (EDIT) reported Research and Development in Process of $27.50 million for the 12-month period ending 2020-12-31, per its 10-K filed 2023-02-22.
Discontinued › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2023-02-22
- EDITAS MEDICINE, INC. research and development in process for the quarter ending 2018-12-31 was $0.00, a 100.00% decline year-over-year.
- EDITAS MEDICINE, INC. research and development in process for the quarter ending 2018-09-30 was $0.00.
- EDITAS MEDICINE, INC. research and development in process for the quarter ending 2018-06-30 was $12.50M.
- EDITAS MEDICINE, INC. research and development in process for the quarter ending 2018-03-31 was $1.94M, a 61.16% decline year-over-year.
- EDITAS MEDICINE, INC. research and development in process for fiscal 2020 was $27.50M.
- EDITAS MEDICINE, INC. research and development in process for fiscal 2018 was $14.44M, a 0.40% decline from fiscal 2017.
- EDITAS MEDICINE, INC. research and development in process for fiscal 2017 was $14.50M, a 45.00% increase from fiscal 2016.
- EDITAS MEDICINE, INC. research and development in process for fiscal 2016 was $10.00M.
| Period end | Research and Development in Process 3 month | Research and Development in Process 6 month | Research and Development in Process 9 month | Research and Development in Process 12 month |
|---|---|---|---|---|
| 2020-12-31 | $27.50M 10-K · filed 2023-02-22 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $0.00 derived: sum of 2 quarters · filed 2021-02-26 | $12.50M derived: sum of 3 quarters · filed 2021-02-26 | $14.44M 10-K · filed 2021-02-26 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $12.50M derived: sum of 2 quarters · filed 2019-11-12 | $14.44M 10-Q · filed 2019-11-12 | $23.94M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-06-30 | $12.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $14.44M 10-Q · filed 2019-08-07 | $23.94M derived: sum of 3 quarters · filed 2020-02-26 | $23.94M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-03-31 | $1.94M 10-Q · filed 2019-05-08 | $11.44M derived: sum of 2 quarters · filed 2020-02-26 | $11.44M derived: sum of 3 quarters · filed 2020-02-26 | $11.44M derived: sum of 4 quarters · filed 2020-02-26 |
| 2017-12-31 | $9.50M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $9.50M derived: sum of 2 quarters · filed 2020-02-26 | $9.50M derived: sum of 3 quarters · filed 2020-02-26 | $14.50M 10-K · filed 2020-02-26 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $0.00 derived: sum of 2 quarters · filed 2018-11-08 | $5.00M 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $5.00M 10-Q · filed 2018-08-07 | ||
| 2017-03-31 | $5.00M 10-Q · filed 2018-05-04 | |||
| 2016-12-31 | $10.00M 10-K · filed 2019-03-01 | |||
| 2014-12-31 | $730.00K 10-K · filed 2017-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |